Contact
Home • Our expertise • Business units • How we help clients • Data and insights • AssetNav

Find your way with AssetNav.

Prioritize pipeline assets.
Optimize your resources.

AssetNav, part of InizioNavigator.ai, is a tool that powers our teams when delivering Asset Prioritization projects. It uses the power of AI and machine learning to help prioritize pipeline assets; supporting commercialization teams to make decisions on how to prioritize their resources and power strategic recommendations.

Powered by People.
Accelerated by AI.

Data and insights are central to what we do. With AssetNav, a product pipeline tool, in our Navigator suite, our teams can help you to quickly identify and prioritize assets, to power smarter decision-making.

 

Strategic

Smart decisions: Enables real-time strategic decision making, with the ability to rapidly refresh data in the future

Visual Insights: Summarized view of data in strategic charts (market, disease, biomarker, asset, trial-level, etc.)

Comparative Scores: Comprehensive scoring across various scientific, regulatory and commercial attributes

Let’s Connect

Predictive

AI & ML Models: Trained machine learning and artificial intelligence models add ability to predict and interpret key insights from trial data such as anticipated time to market, patient-type categorization, expected line of therapy, and other results

Let’s Connect

Real-time

Deeper insights. Faster: Real time access to pre-structured / merged data from 10+ sources providing instant access to deeper insights, at the touch of a button

Instant Filtering: Ability to instantly distil and restructure information or present multiple assets on a prioritized basis.

Let’s Connect

Impact by numbers.

15+

Data sources covered

46

Diseases

~20,000

Unique assets

~200,000

Trials

~3,000

Mechanisms of action

17

In-house algorithms

Experts in Asset Prioritization.

Joseph Feingold

Partner, Portfolio, Licensing & Development Practice Lead & Head of Advanced Technologies Center of Excellence, Putnam

A neuroscientist turned biotech strategy expert with deep experience navigating complex challenges in global markets, Joseph combines scientific and entrepreneurial skillsets to perform rigorous analysis and deliver critical insights to biopharma, diagnostics, and medical device leaders.

Joseph supports a range of clients across therapeutic areas and modalities, with particular focus on hematology / oncology, neurology, and rare diseases, developing strategies for pipeline products and portfolios to guide BD, clinical development, and commercialization. An expert on novel technologies, Joseph heads Putnam’s center of excellence on advanced technologies, including cell and gene therapies, requiring sophisticated hospital-based administration and development of new commercialization models.

Read more

John L’Ecuyer

Executive Director, Business Development, Putnam

As part of Putnam’s Portfolio, Licensing & Development practice, John helps clients build clinical development and go-to-market strategies.

Across therapy areas, he has helped clients drive strategic prioritization decisions about where to position their early-stage assets in the future treatment paradigm, how to determine the target profile and clinical development path required to win and differentiate, and how to size the opportunity and weigh trade-offs.

He joined SmartAnalyst (now part of Putnam) in 2003 and has partnered with biopharma clients in North America, Europe, and Asia-Pacific to provide data-driven strategies and insights that inform important clinical development and investment decisions. Prior to SmartAnalyst, he worked in healthcare communications, where he supported media relations for healthcare providers and biotech companies.

Read more

Get in touch.

Let us help you find your way.